Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Investors Are Sitting on a Loss of 51% If They Invested Five Years Ago
While not a mind-blowing move, it is good to see that the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) share price has gained 14% in the last three months. But that can't change t
Shenzhen Hepalink Shareholders Approve Key Resolutions
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Hyperlink (002399.SZ/9989.HK): 2024Q1 net profit to mother increased 133% year-on-year, steady operation continued to improve
In an environment where the external market is still full of uncertainty, the disclosure of the 2023 report and 2024 quarterly report related to A-shares has come to an end. Looking back at 2023, companies related to the heparin industry faced quite a few challenges under stress tests in the face of declining pig cycles. However, at the beginning of 2024, along with the gradual stabilization of the bottom of pig prices, some leading companies have improved significantly and shown strong resilience. Among them, Hapley, a leading company in the heparin industry, also handed over a report in the first quarter of 2024 with a 133% year-on-year increase in net profit, outperforming the industry's performance during the same period. Hypri publishes quarterly report
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
Why Investors Shouldn't Be Surprised By Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 2.8x Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) is a stock worth checking out, seeing as almost half of all the Pharmac
Changes in Hong Kong stocks | Hapley (09989) A shares rose or stopped, and H shares once rose more than 11%, net profit to mother increased 1.33 times year-on-year in the first quarter
Hypry (09989) A-shares rose to a halt. As of press release, H shares rose 8.59% to HK$3.54, with a turnover of HK$124.367 million.
海普瑞:2023年報
Hyperion (09989) plans to renew Ernst & Young Huaming and EY as auditors
Haipuri (09989) issued an announcement. Shenzhen Haipuri Pharmaceutical Group Co., Ltd. was announced on April 29, 2024...
Hapley (09989) announced first-quarter results, net profit of 155 million yuan, up 133% year-on-year
Hapley (09989) announced its results for the first quarter of 2024, with revenue of 1,373 billion yuan, an increase of 5...
海普瑞:二零二四年第一季度報告
Zhitong Hong Kong Stock Investment Calendar | April 29
According to statistics from the Zhitong Finance App, on April 29, 2024, the investment log of Hong Kong stock listed companies is as follows: Category Company Performance Announcement Date: Bank of Zhengzhou Xinte Energy China Galaxy China Communications Construction Hyperion Fosun Pharmaceuticals CRRC Red Star Macalline Shanghai Electric Dongfang Electric Shareholders' Meeting Held Japan-China Guangzhou Nuclear Power Jilin Changlong Pharmaceutical Seaport Enterprise Delin International Asia Backup CLP Holdings Pacific Network China Building Materials Dividend Shenwei Pharmaceutical (excluding Clean Day) Comfort Project (dividend day) Chunquan Industrial Trust (dividend date) 361 degrees (excluding cleaning day) Prada (excluding clean day) ) Times Group Holdings (dividends)
Hyperlink (09989.HK) held a board meeting on April 29 to consider and approve the first quarter results
On April 16, GLONGHUI (09989.HK) announced that the company will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's first quarter results for the three months ended March 31, 2024 and their publication.
Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane
Shenzhen Hepalink Pharmaceutical Group's (HKG:9989, SHE:002399) enoxaparin sodium injection, Exarane, has been approved by the Thailand Food and Drug Administration for sales in the market, a Tuesday
Hipry (09989.HK): EXARANE obtains approval from Thailand
On April 2, Gelonghui (09989.HK) announced that Exarane (one of the Group's leading drugs for enoxaparin sodium injections) produced by its wholly-owned subsidiary Shenzhen Tiandao Pharmaceutical Co., Ltd., has been approved for marketing by the Thai Food and Drug Administration. The announcement stated that with this approval, the ennoxaparin sodium formulation representing the Group Hypree will be sold in the Thai market, which will further increase the global market share of the Group's enoxaparin sodium preparations. The Group believes that this approval is another important achievement in implementing the international layout of the Group's pharmaceutical business, once again proving that the Group has entered overseas markets
Hapley (09989): A total of 1 billion yuan in preparation for impairment in 2023
Hyperlink (09989) issued an announcement that Shenzhen Haipuri Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”)...
Hapley (09989) plans to carry out foreign exchange derivatives transactions for hedging purposes with a total value of no more than 350 million US dollars
Hipry (09989) issued an announcement. In order to reduce foreign exchange risk and enhance financial stability, Shenzhen Haipuri Pharmaceutical Group...
Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Is Making Moderate Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Hapley (002399.SZ) announced its 2023 annual results, with a net loss of 783 million yuan, changing from profit to loss
According to the Zhitong Finance App, Hapley (002399.SZ) released its 2023 annual report. The company's operating income was 5.446 billion yuan, down 23.94% from the previous year; net loss attributable to shareholders of listed companies was 783 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 780 million yuan, which changed from profit to loss; basic loss per share was 0.5338 yuan/share. During the reporting period, the company's heparin industry chain business achieved sales revenue of RMB 4.287 billion, a year-on-year decrease of 27.15%. Formulation sales remained stable, achieving sales revenue of RMB 2,979 billion
Hyperion (002399.SZ): Enoxaparin sodium injection obtained New Zealand drug registration approval
Haipuri (002399.SZ) announced that the company's wholly-owned subsidiary, Shenzhen Tiandao Pharmaceutical Co., Ltd. (abbreviated as “Tiandao...
No Data